Corthera adds $10M for heart failure medication
Pharmaceutical company Corthera just took $10 million to close a $23 million third round of funding but is already looking to raise $40 to $50 million in a new fourth round by March to support clinical trials of a drug that could ease symptoms of heart failure, reports VentureWire. Poised for phase three clinical trials, the drug, called Relaxin, is actually a hormone capable of relieving the lung fluid congestion and hypertension that accompany heart… Continue Reading
Life sciences briefing: Friday, Dec. 21, 2007
TODAY’S HEADLINES:
Cogentus Pharma raises $63M for blood thinners (release)
Corthera draws $23M for heart-failure drug (release)
Nanolymf seeks $2M for drug-delivery tech (release)
LineaGen pulls in $5.6M for molecular diagnostics (release)
Cogentus Pharma raises $63M for blood thinners — Menlo Park, Calif.-based Cogentus Pharmaceuticals, a specialty pharma developing combined formulations of existing drugs, raised $62.5 million in a third funding round. Investors included Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital and Pinnacle Ventures.
Cogentus aims to combine existing… Continue Reading